Table 2.
HBV surface antigen positive rituximab-associated HBV reactivation: case reports
| Author | NHL type | Age/gender | Comorbidity | Received prophylaxis (lamivudine) | Prior immunosuppressive therapy | Concurrent immune suppressants | Time to reactivate from first rituximab | Doses of rituximab | Time to reactivate from last rituximab | Liver outcome | Treatment of reactivation (drug) | Death |
| Tsutsumi et al. [39] | DLBCL | 68/F | None | No | None | CHOP | 4 months | 3 | 3 months | Liver failure | Yes (lamivudine) | Yes |
| Dai et al. [20] | DLBCL | 21/M, 33/M, 41/F, 42/M | None | Yes (through 4 weeks after R-CHOP) | None | CHOP (all pts) | 8–12 months | 6 (all pts) | 4, 6, 6, and 8 months | Hepatitis | Yes (lamivudine—all) | None |
| Law et al. [40] | FL | 57/M | None | Yes | None | CHOP | 9 months | 6 | 5 months | Liver failure | Yes (tenofovir; lamivudine resistant) | Yes |
| Perceau et al. [23] | Cutan NHL | 78/F | None | No | CVP 6 years prior, CEP 2 year prior | None | 13 months | 4 | 12 months | Liver failure | Yes (lamivudine) | Yes |
| Kaled et al. [41] | WM | 32/F | None | No | None | Fludarabine | 9 months | 7 | 5 months | Hepatitis | Yes (lamivudine and adefovir) | No |
| Yang et al. [24] | FL | 41/F | None | No | Leukeran 1 year prior | None | 13 months | 4 | 12 months | Hepatitis | Yes (lamivudine) | No |
| Marino et al. [42] | DLBCL | 59/M | None | No | None | CHOP | 9 months | 8 | 3 months | Liver failure | Yes (lamivudine resistant) | Yes |
| Wasmuth et al. [43] | Indolent NHL | 55/M | None | No | None | Fludarabine based | 6 months | 6 | 2 months | Liver failure | Yes (lamivudine) | Yes |
| He et al. [22] | DLBCL | 29/F | None | Yes | None | Chemotherapy | 12 months | NR | 7 months | Hepatitis | Yes (lamivudine) | No |
| Dillon et al. [44] | DLBCL | 21/F | None | No | None | CHOP | 3 months | 4 | 0 months | Liver failure | Yes (lamivudine) | Yes |
| Aomatsu et al. [45] | DLBCL | 57/F | None | No | No | CHOP | 10 months | 6 | 5 months | Liver failure | Yes (lamivudine and plasma exchange) | Yes |
| Taiwan active surveillance, 2009 | SLL | 56/M | None | Yes (lamivudine) | R-CVP × 8 (1 year prior) and rituximab maintenance | No | 14 months | 10 | 1 month | Hepatitis | Yes (adefovir and entecavir; lamivudine resistant) | No |
NHL, non-Hodgkin's lymphoma; FL, follicular lymphoma; WM, Waldenstroms macroglobulinemia; SLL, small lymphocytic lymphoma; M, male; F, female; Cutan, cutaneous; pts, patients; HBV Hepatitis B virus; DLBCL, diffuse large B-cell lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CVP, rituximab, cyclophosphamide vincristine, prednisone; CEP, cyclophosphamide, etoposide, prednisone; NR, not reported.